LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients

Annals of Clinical and Translational Neurology

Volumn 1, Issue 2, 2014, Pages 80-87

  Tzartos, John S ^a,b   Zisimopoulou, Paraskevi ^a   Rentzos, Michael ^c   Karandreas, Nikos ^c   Zouvelou, Vasiliki ^c   Evangelakou, Panagiota ^a,d   Tsonis, Anastasios ^a,d   Thomaidis, Thomas ^b   Lauria, Giuseppe ^e   Andreetta, Francesca ^e   Mantegazza, Renato ^e   Tzartos, Socrates J ^a,c  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; LRP4 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION;

EID: 84922238328     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.26     Document Type: Article

References (27)

1. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12:310-322.
2. Hovden H, Frederiksen JL, Pedersen SW. Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol Scand 2013; doi:10.1111/ane.12125. [Epub ahead of print].
3. Rentzos M, Rombos A, Nikolaou C, et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand 2010;122:425-429.
4. Sta M, Sylva-Steenland RM, Casula M, et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 2011;42:211-220.
5. Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int 2011;2011:497080.
6. Ludolph AC. Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:13-14.
7. Joyce NC, Carter GT. Electrodiagnosis in persons with amyotrophic lateral sclerosis. PM R 2013; doi:10.1016/j. pmrj.2013.03.020.
8. Mulder DW, Lambert EH, Eaton LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959;9:627-631.
9. Weatherbee SD, Anderson KV, Niswander LA. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006;133: 4993-5000.
10. Tian QB, Suzuki T, Yamauchi T, et al. Interaction of LDL receptor-related protein 4 (LRP4) with postsynaptic scaffold proteins via its C-terminal PDZ domain-binding motif, and its regulation by Ca/calmodulin-dependent protein kinase II. Eur J Neurosci 2006;23:2864-2876.
11. Wu H, Lu Y, Shen C, et al. Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 2012;75:94-107.
12. Yumoto N, Kim N, Burden SJ. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012;489:438-442.
13. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010;43:371-379.
14. Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69: 418-422.
15. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259:427-435.
16. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-451.
17. Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006;9:408-419.
18. Lu Y, Tian QB, Endo S, et al. A role for LRP4 in neuronal cell viability is related to apoE-binding. Brain Res 2007;26:19-28.
19. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131:1940-1952.
20. Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 2013;123: 5190-5202.
21. Fischer LR, Glass JD. Axonal degeneration in motor neuron disease. Neurodegener Dis 2007;4:431-442.
22. Wolfgram F. Blind studies on the effect of amyotrophic lateral sclerosis sera on motor neurons in vitro. UCLA Forum Med Sci 1976;(19):145-149.
23. Roisen FJ, Bartfeld H, Donnenfeld H, et al. Neuron specific in vitro cytotoxicity of sera from patients with amyotrophic lateral sclerosis. Muscle Nerve 1982;5:48-53.
24. Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984;6:51-57.
25. Olarte MR, Schoenfeldt RS, McKiernan G, et al. Plasmapheresis in amyotrophic lateral sclerosis. Ann Neurol 1980;8:644-645.
26. Brown RH Jr, Hauser SL, Harrington H, et al. Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 1986;43:383-384.
27. Drachman DB, Chaudhry V, Cornblath D, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-150.